Table 4 |
|||||||
|
Autoantibodies in different disease subsets in 863 individual systemic sclerosis patients |
|||||||
|
Limited (N = 513) |
Diffuse (N = 173) |
Overlap (N = 108) |
Undifferentiated (N = 64) |
||||
|
|
|||||||
|
Antibodies |
n (%) |
ORa (P-value) |
n (%) |
OR (P-value) |
n (%) |
OR (P-value) |
n (%) |
|
|
|||||||
|
ACA |
253 (49.3) |
5.00 (P < 0.0001) |
12 (6.9) |
16 (14.8) |
28 (43.8) |
||
|
ATA |
141 (27.5) |
98 (56.6) |
4.26 (P < 0.0001) |
11 (10.2) |
9 (14.1) |
||
|
Anti-RNAP |
14 (2.7) |
14 (8.1) |
3.11 (P = 0.0029) |
2 (1.9) |
2 (3.1) |
||
|
Anti-U1-RNP |
7 (1.4) |
0 (0.0) |
31 (28.7) |
30.00 (P < 0.0001) |
2 (3.1) |
||
|
Anti-PM-Scl |
16 (3.1) |
2 (1.2) |
22 (20.4) |
9.40 (P < 0.0001) |
2 (3.1) |
||
|
Anti-fibrillarin |
3 (0.6) |
8 (4.6) |
8.32 (P = 0.0005) |
1 (0.9) |
0 (0.0) |
||
|
Anti-To |
1 (0.2) |
0 (0) |
1 (0.9) |
0 (0.0) |
|||
|
Anti-Jo-1/Pl-7/OJ |
0 (0.0) |
0 (0) |
4 (3.7) |
65.07 (P = 0.0002) |
0 (0.0) |
||
|
Anti-U11-RNP |
0 (0.0) |
1 (0.6) |
0 (0.0) |
0 (0.0) |
|||
|
Anti-Ku |
5 (1.0) |
1 (0.6) |
3 (2.8) |
1 (1.6) |
|||
|
Anti-SL |
5 (1.0) |
3 (1.7) |
1 (0.9) |
0 (0.0) |
|||
|
Anti-Sm |
0 (0.0) |
0 (0.0) |
3 (2.8) |
21.54 (P = 0.0069) |
0 (0.0) |
||
|
Anti-NOR-90 |
5 (1.0) |
0 (0.0) |
1 (0.9) |
0 (0.0) |
|||
|
AMA |
28 (5.5) |
4 (2.3) |
4 (3.7) |
5 (7.8) |
|||
|
Anti-Sp100 |
3 (0.6) |
0 (0.0) |
0 (0.0) |
1 (1.6) |
|||
|
Anti-Ro52 |
125 (24.4) |
1.50 (P = 0.023) |
20 (11.6) |
27 (25.0) |
15 (23.4) |
||
|
Anti-Ro60 |
28 (5.4) |
14 (8.1) |
13 (12.0) |
2.11 (P = 0.0382) |
4 (6.3) |
||
|
Anti-La |
9 (1.8) |
3 (1.7) |
1 (0.9) |
3 (4.7) |
|||
|
Anti-p25/p23 |
24 (4.5) |
4.25 (P = 0.0031) |
0 (0.0) |
2 (1.9) |
2 (3.1) |
||
|
Other |
209 (40.7) |
74 (42.8) |
44 (40.7) |
34 (53.1) |
|||
|
ANA-negative |
32 (6.2) |
6 (3.5) |
5 (4.6) |
7 (10.9) |
|||
|
|
|||||||
|
ACA, anti-centromere antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; ATA, anti-topoisomerase I antibodies; RNAP, RNA polymerase;. aOR for antibody in that subset compared with all other subsets. Only significant positive associations are documented by OR, and those with P-values < 0.005 are printed in bold. |
|||||||
|
Mierau et al. Arthritis Research & Therapy 2011 13:R172 doi:10.1186/ar3495 |
|||||||
